Δημοσιεύσεις

 Giannakopoulou SP, Barkas F, Chrysohoou C, Liberopoulos E, Sfikakis PP, Pitsavos C, Tsioufis C, Panagiotakos D. Comparative analysis of obesity indices in discrimination and reclassification of cardiovascular disease risk: The ATTICA study (2002-2022). Eur J Intern Med 2025;134:96-103. doi: 10.1016/j.ejim.2025.02.007

Elshorbagy A, Vallejo-Vaz AJ, Barkas F, Lyons ARM, Stevens CAT, Dharmayat KI, Catapano AL, Freiberger T, Hovingh GK, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Alhabib KF, Alkhnifsawi M, Almahmeed W, Alnouri F, Alonso R, Al-Rasadi K, Al-Sarraf A, Arca M, Ashavaid TF, Averna M, Banach M, Becker M, Binder CJ, Bourbon M, Brunham LR, Chlebus K, Corral P, Cruz D, Davletov K, Descamps OS, Dwiputra B, Ezhov M, Groselj U, Harada-Shiba M, Holven KB, Humphries SE, Kayikcioglu M, Khovidhunkit W, Lalic K, Latkovskis G, Laufs U, Liberopoulos E, Lima-Martinez MM, Maher V, Marais AD, März W, Mirrakhimov E, Miserez AR, Mitchenko O, Nawawi H, Nordestgaard BG, Panayiotou AG, Paragh G, Petrulioniene Z, Pojskic B, Postadzhiyan A, Reda A, Reiner Ž, Reyes X, Sadiq F, Sadoh WE, Schunkert H, Shek AB, Stroes E, Su TC, Subramaniam T, Susekov AV, Tilney M, Tomlinson B, Truong TH, Tselepis AD, Tybjærg-Hansen A, Vázquez-Cárdenas A, Viigimaa M, Vohnout B, Yamashita S, Ray KK. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J 2025;46:1127-1140. doi: 10.1093/eurheartj/ehae791

Stevens CAT, Vallejo-Vaz AJ, Chora JR, Barkas F, Brandts J, Mahani A, Abar L, Sharabiani MTA, Ray KK. Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution? J Am Heart Assoc 2024;13:e034434. doi: 10.1161/jaha.123.034434

Karakasis P, Patoulias D, Barkas F, Theofilis P, Milionis H, Doumas M, Kassimis G, Tsioufis K, Fragakis N. Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials. Hellenic J Cardiol 2024. doi: 10.1016/j.hjc.2024.06.005

Barkas F, Sener YZ, Golforoush PA, Kheirkhah A, Rodriguez-Sanchez E, Novak J, Apellaniz-Ruiz M, Akyea RK, Bianconi V, Ceasovschih A, Chee YJ, Cherska M, Chora JR, D'Oria M, Demikhova N, Kocyigit Burunkaya D, Rimbert A, Macchi C, Rathod K, Roth L, Sukhorukov V, Stoica S, Scicali R, Storozhenko T, Uzokov J, Lupo MG, van der Vorst EPC, Porsch F. Advancements in risk stratification and management strategies in primary cardiovascular prevention. Atherosclerosis 2024;395:117579. doi: 10.1016/j.atherosclerosis.2024.117579

Barkas F, Rizos CV, Liamis G, Skoumas I, Garoufi A, Rallidis L, Kolovou G, Tziomalos K, Skalidis E, Sfikas G, Kotsis V, Doumas M, Anagnostis P, Lambadiari V, Anastasiou G, Koutagiar I, Attilakos A, Kiouri E, Kolovou V, Polychronopoulos G, Koutsogianni AD, Zacharis E, Koumaras C, Antza C, Boutari C, Liberopoulos E. Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry. J Clin Lipidol 2024;18:e394-e402. doi: 10.1016/j.jacl.2024.01.005

Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother 2024;25:349-358. doi: 10.1080/14656566.2024.2337253

Barkas F, Liberopoulos E, Rizzo M. Exploring the Landscape of Familial Hypercholesterolemia: Unraveling Genetic Complexity and Clinical Implications. Eur J Intern Med 2024;123:58-59. doi: 10.1016/j.ejim.2024.02.031

Adamou A, Barkas F, Milionis H, Ntaios G. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials. Int J Stroke 2024;19:876-887. doi: 10.1177/17474930241253988

Panagiotakos D, Chrysohoou C, Damigou E, Barkas F, Liberopoulos E, Tsioufis C, Sfikakis PP, Pitsavos C. Prediction of lifetime risk for cardiovascular disease, by risk factors level: the ATTICA epidemiological cohort study (2002-2022). Ann Epidemiol 2023;87:17-24. doi: 10.1016/j.annepidem.2023.09.010

Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Filippatos TD, Ray KK, Agouridis AP. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association? Atheroscler Plus 2023;54:1-6. doi: 10.1016/j.athplu.2023.09.001

Barkas F, Ray KK. The global diagnostic network: what can we learn from half a billion lipid measurements between 2018 and 2020? Eur Heart J 2023;44:2319-2321. doi: 10.1093/eurheartj/ehad308

Barkas F, Bathrellou E, Nomikos T, Panagiotakos D, Liberopoulos E, Kontogianni MD. Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention. Nutrients 2023;15. doi: 10.3390/nu15132845

Anastasiou G, Liberopoulos E, Petkou E, Koutsogianni AD, Adamidis PS, Liamis G, Ntzani E, Barkas F. Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin-Therapy: A 6-Year Retrospective Study. Diagnostics (Basel) 2023;13. doi: 10.3390/diagnostics13030503

Koutsogianni AD, Adamidis PS, Barkas F, Liberopoulos E, Su TC, Yamashita S, Liamis G, Rizzo M. Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention. Metabolites 2022;12. doi: 10.3390/metabo12111065

Barkas F, Ntekouan SF, Liberopoulos E, Filippatos T, Milionis H. Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis 2021;30:105708. doi: 10.1016/j.jstrokecerebrovasdis.2021.105708

Barkas F, Adamidis P, Koutsogianni AD, Liamis G, Liberopoulos E. Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study. Arch Med Sci Atheroscler Dis 2021;6:e182-e187. doi: 10.5114/amsad.2021.111313

Barkas F, Nomikos T, Liberopoulos E, Panagiotakos D. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis. Nutrients 2020;12. doi: 10.3390/nu12082436

Barkas F, Liamis G, Elisaf M, Anastasiou G, Liberopoulos E. Metabolically healthy obesity and risk of incident type 2 diabetes in 1077 statin-treated individuals: A six-year retrospective study. Eur J Prev Cardiol 2020;27:2341-2344. doi: 10.1177/2047487319899191

Barkas F, Elisaf M, Rizos EC, Liberopoulos E. Bridging the treatment gap in patients at 'extreme' cardiovascular risk: Evidence from a lipid clinic. Atherosclerosis 2019;281:216-218. doi: 10.1016/j.atherosclerosis.2018.11.022

Barkas F, Elisaf M, Milionis H. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. Eur J Neurol 2019;26:559-565. doi: 10.1111/ene.13905

Barkas F, Elisaf M, Tsimihodimos V, Milionis H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. Diabetes Metab 2017;43:1-8. doi: 10.1016/j.diabet.2016.10.006

Milionis H, Barkas F, Ntaios G, Papavasileiou V, Vemmos K, Michel P, Elisaf M. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk. Eur J Intern Med 2016;34:54-57. doi: 10.1016/j.ejim.2016.06.023

Barkas F, Elisaf M, Liberopoulos E, Liontos A, Rizos EC. High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. Atherosclerosis 2016;247:58-63. doi: 10.1016/j.atherosclerosis.2016.02.001

Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos EC. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol 2016;10:306-313. doi: 10.1016/j.jacl.2015.11.015

Barkas F, Elisaf M, Milionis H. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. Atherosclerosis 2015;243:60-64. doi: 10.1016/j.atherosclerosis.2015.08.038